| August 20, 2004 |
|
|
|
|
|
Discontinuation of MSP Requirement for Hospitals
|
|
Effective Date: December 8, 2003
Implementation Date: August 16, 2004
Hospitals are no longer required to collect Medicare Secondary Payer (MSP) information where there is no face-to-face
encounter with a beneficiary.
Reference: Medlearn Matters MM3267.
Related CR: 3267,
Transmittal 17.
|
|
Duplicate Claims Submissions
|
|
Effective Date: October 1, 2004
CMS asks providers to discontinue the practice of routinely resubmitting duplicate claims. If you submit more than once for
the same service on the same date of service, your claim will be denied as a duplicate. In addition, duplicate claims:
1) may delay payment; 2) could cause you to be identified as an abusive biller; 3) if a pattern of duplicate billing
is identified, may generate an investigation for fraud.
Reference: MMSE0415.
|
|
Medicare Physician Fee Schedule Update
|
|
Effective Date: January 01, 2004 (Retroactive)
This is the 2nd update to the 2004 Medicare Physician Fee Schedule Database, and includes the following changes:
| |
Code |
Mod |
Description |
Amount |
| |
88358 |
|
Non-Facility PE RVU
Facility PE RVU |
$58.91 |
| |
88358 |
TC |
Non-Facility PE RVU
Facility PE RVU |
$6.31 |
| |
88358 |
26 |
Non-Facility PE RVU
Facility PE RVU |
$52.60 |
Reference: MM3286,
CR: 3286; Transmittal: 173
|
|
Process To Resubmit Minor Claim Errors
|
|
Effective Date: October 1, 2004
Implementation Date: October 4, 2004
The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) requires a process for physicians, providers, and
suppliers to correct minor errors and omissions on claims without pursuing
the formal appeals process.
Reference: Medlearn Matters SE0420.
|
|
High Sensitivity C-Reactive Protein
|
|
Publication Date August 05, 2004
An article published in Medicare B Resource for June 2003 (page 21) announced that Medicare considered High sensitivity C-reactive protein
to be used as a screening test only and therefore not reimbursable. This policy is being revised based on updated information. High
sensitivity C-reactive protein (hsCRP) (CPT code 86141) has been found to be related to or somewhat predictive of atherogenic risk for
cardiovascular disease or stroke. Recent literature supports this as the principal use of hsCRP. Effective immediately, NHIC-California
will consider hsCRP (CPT 86141) for payment as part of the overall evaluation and treatment plan indicated for the signs or symptoms
of disease. In the absence of signs or symptoms of disease, use of hsCRP as a screening test remains non covered by Medicare. In
addition, where appropriate, the less costly standard CRP test (CPT 86140) should be considered.
Reference: California Providers,
Updates.
|
|
LMRPs
|
|
Effective Date October 01, 2004
Trailblazer – Virginia has published their Local Medical Review Policies (LMRPs) in their August News letter.
Reference: Part B Medicare,
Newsletter.
|
|
Medi-Cal Update – Billing and Policy
|
|
Electronic Submission of Laboratory Services with Medical Justification
Effective for dates of service on or after September 1, 2004, providers may electronically bill for laboratory services
(CPT-4 80000 series codes and HCPCS Level III codes) that require medical justification by entering the medical justification in
the electronic filing Remarks area of the transaction. Medical justification statements entered in the electronic filing Remarks
area must not exceed 1,500 characters. If the statement exceeds the character limit, providers must submit a paper claim with the
appropriate medical justification documents accompanying the claim. Claims and "By Report" attachments for the following CPT-4 and
HCPCS codes may not be submitted electronically:
| |
CPT-4 / HCPCS Codes |
Description |
| |
83013 |
Helicobacter pylori; analysis for urease activity, non-radioactive isotope |
| |
83014 |
drug administration and sample collection |
| |
87620 |
Papillomavirus, human, direct probe technique |
| |
87621 |
amplified probe technique |
| |
87901 |
Infectious agent genotype analysis by nucleic acid (DNA or RNA); HIV 1, reverse transcriptase and protease |
| |
87902 |
Hepatitis C virus |
| |
87903 |
Infectious agent phenotype analysis by nucleic acid (DNA or RNA) with drug resistance tissue culture analysis,
HIV 1; first through 10 drugs tested |
| |
87904 |
each additional 1 through 5 drugs tested |
| |
Z2004 |
Surgical pathology, gross and microscopic examination of presumptively normal tissue(s) obtained in conjunction
with abortion procedure |
|
This information is reflected on manual replacement page
path bil 6s (Part 2).
Reference: Medi-Cal Publications.
|
|
|
2005 ICD-9-CM Diagnosis Codes
|
|
No Implementation Grace Period
Effective Date: October 1, 2004
The HIPAA Transaction and Code Set Rule requires the use of national/medical code sets (such as ICD-9s) that are valid at
the time the service is rendered. All claims for services on or after October 1, 2004 must adhere to the 2005 diagnosis code
changes.
In past years, ICD-9 codes became effective for Medi-Cal in January or February. Though code updates were released in October,
Medi-Cal implementation was delayed to coincide with Medicare implementation. Medi-Cal allowed a 90-day grace period to allow you
to become familiar with the new codes and learn about discontinued codes.
This year there is no grace period for use of the codes on claim submissions.
Refer to the 2005 International Classification of Diseases, 9th Revision, Clinical Modification, 6th Edition (ICD-9-CM book) for
code descriptions.
|
Reference: Medi-Cal Publications.
|
|
| |
|
| |
|
Return to Top
|
|
Contact Us | Privacy Statement |
Legal
|
| © 2004 XIFIN®, Inc. All rights reserved.
|
|
|